(Q39559712)

English

Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance

scientific article published on April 12, 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance (English)

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

0 references

1 reference

based on heuristic

inferred from title

author name string

Milos Dokmanovic

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yi Shen

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Wen Jin Wu

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Tabetha M. Bonacci

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21487052

29 November 2024

Dianne S. Hirsch

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21487052

29 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21487052

29 November 2024

publication date

12 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

917-928

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Trastuzumab--mechanism of action and use in clinical practice

1

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

2

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

3

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Her2 cross talk and therapeutic resistance in breast cancer

4

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

5

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer

6

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

7

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

8

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

9

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

10

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

11

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Role of insulin-like growth factor binding proteins in mammary gland development

12

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

13

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Cellular actions of the insulin-like growth factor binding proteins

14

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Insulin-like growth factor binding proteins and breast cancer

15

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast Cancer Cells

16

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Proteomics demonstration that normal breast epithelial cells can induce apoptosis of breast cancer cells through insulin-like growth factor-binding protein-3 and maspin.

17

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells

18

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo

19

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes

21

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex

22

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells

23

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Pilot Study of Elevated Levels of Insulin-Like Growth Factor-Binding Protein-2 as Indicators of Hepatocellular Carcinoma

24

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors

25

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Transactivation of the IGFBP-2 promoter in human tumor cell lines

26

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer

27

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer

28

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.

29

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2.

30

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells

31

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

32

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

33

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

34

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Activated Cdc42 Sequesters c-Cbl and Prevents EGF Receptor Degradation

36

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathway

37

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation

38

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42.

39

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

40

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer

41

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer

42

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

43

1 reference

10.1158/1535-7163.MCT-10-0980

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0980

29 November 2024

Identifiers

10.1158/1535-7163.MCT-10-0980

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39559712&oldid=2282426932"